RxSight (RXST) Net Income towards Common Stockholders (2020 - 2026)

RxSight (RXST) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$15.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 93.94% year-over-year to -$15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.6 million (down 76.31% YoY) and the FY2025 annual result came in at -$38.9 million, down 27.48% from the prior year.
• Net Income towards Common Stockholders eased to -$15.9 million in Q1 2026, from -$9.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $53.5 million in Q4 2022 to a low of -$17.6 million in Q1 2022.
• A 5-year average of -$4.1 million and a median of -$9.8 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 440.07% in 2022, down 158.57% in 2022.
• Tracing RXST's Net Income towards Common Stockholders over 5 years: stood at $53.5 million in 2022, then retreated by 7.23% to $49.6 million in 2023, then slumped by 111.78% to -$5.8 million in 2024, then sank by 56.55% to -$9.2 million in 2025, then sank by 73.56% to -$15.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$15.9 million (Q1 2026), -$9.2 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.